Journal
MICROBES AND INFECTION
Volume 4, Issue 13, Pages 1301-1307Publisher
ELSEVIER
DOI: 10.1016/S1286-4579(02)00008-4
Keywords
poliovirus; RNA-dependent RNA polymerase; evolution; quasispecies; hepatitis C virus
Categories
Funding
- NIAID NIH HHS [AI40085] Funding Source: Medline
Ask authors/readers for more resources
The antiviral drug ribavirin exhibits strong antiviral activity against a broad range of RNA viruses. This drug is currently used clinically to treat hepatitis C virus infections, respiratory syncytial virus infections, and Lassa fever virus infections. Although ribavirin was discovered in 1972, its mechanism of action has remained unclear until recently. Using poliovirus as an RNA virus model, it was shown that ribavirin is a virus mutagen, and it was proposed that the primary mechanism of action of ribavirin is via lethal mutagenesis of the RNA virus genomes. This represents a novel antiviral mechanism of action and provides a model for the development of new antiviral strategies. In this review we discuss the genetic explanations, evolutionary implications, and drug development opportunities associated with RNA virus mutagenesis. (C) 2002 Editions scientifiques et medicales Elsevier SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available